Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Rapidly Shifting Ketamine Landscape in the US.
Wilkinson ST, Palamar JJ, Sanacora G. Wilkinson ST, et al. JAMA Psychiatry. 2024 Mar 1;81(3):221-222. doi: 10.1001/jamapsychiatry.2023.4945. JAMA Psychiatry. 2024. PMID: 38170542
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.
Kitay BM, Murphy E, Macaluso M, Corlett PR, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee TG, Sanacora G, Shelton RC, Thase ME, Wilkinson ST. Kitay BM, et al. Among authors: wilkinson st. Psychiatry Res. 2023 Dec;330:115585. doi: 10.1016/j.psychres.2023.115585. Epub 2023 Oct 30. Psychiatry Res. 2023. PMID: 37935086
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P. Castro M, et al. Among authors: wilkinson st. CNS Drugs. 2023 Aug;37(8):715-723. doi: 10.1007/s40263-023-01026-3. Epub 2023 Aug 9. CNS Drugs. 2023. PMID: 37558912 Free PMC article.
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. Anand A, et al. Among authors: wilkinson st. N Engl J Med. 2023 Jun 22;388(25):2315-2325. doi: 10.1056/NEJMoa2302399. Epub 2023 May 24. N Engl J Med. 2023. PMID: 37224232 Clinical Trial.
Trends in Illicit Ketamine Seizures in the US From 2017 to 2022.
Palamar JJ, Wilkinson ST, Carr TH, Rutherford C, Cottler LB. Palamar JJ, et al. Among authors: wilkinson st. JAMA Psychiatry. 2023 Jul 1;80(7):750-751. doi: 10.1001/jamapsychiatry.2023.1423. JAMA Psychiatry. 2023. PMID: 37223891
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ. Zaki N, et al. Among authors: wilkinson st. Neuropsychopharmacology. 2023 Jul;48(8):1225-1233. doi: 10.1038/s41386-023-01577-5. Epub 2023 May 12. Neuropsychopharmacology. 2023. PMID: 37173512 Free PMC article. Clinical Trial.
108 results